The extension of the alliance with the University of Oxford enhances Summit’s capabilities in the DMD field, providing access to academic research groups at Oxford and assisting in accelerating the development of future generation molecules. The group’s lead utrophin modulator, SMT C1100, is due to commence a Phase II open label trial in Q4 2015. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europe, which affects around 1 in 3,500 male births, and unlike ....
